LOS ANGELES, CA / ACCESS Newswire / February 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has ...

Rising prevalence of diabetes, recent product approvals & product launches in the market are the major factors driving the market for incretin-based drugs.

The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct ...

Incretin-mimetic drugs contribute to dramatic weight loss, but this does not solely mean fat loss. In this article, we ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

Two months after launching Pep2Tango Therapeutics, VC firm Versant Ventures is unveiling another obesity-focused biotech in ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Novo Nordisk's amycretin trial results highlight significant weight loss in adults with obesity, with further clinical ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...